Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Brutons tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK[1][2].
Molekulargewicht:
427.50
Reinheit:
99.97
CAS Nummer:
[1655504-04-3]
Formel:
C26H25N3O3
Target-Kategorie:
Btk
Anwendungsbeschreibung:
MCE Product type: Reference compound1
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten